Reta glucagon-like peptide-1 (GLP-1) receptor agonists provide a groundbreaking approach to diabetes management. These innovative drugs function by mimicking the inherent actions of GLP-1, a hormone released by the gut in response to food. By triggering GLP-1 receptors in the pancreas, these agents boost insulin secretion and suppress glucagon outp

The burgeoning landscape of novel treatments for weight management has seen the rise of both retatrutide and tirzepatide, both dual approach agonists targeting the GLP-1 and GIP receptors. While sharing a comparable therapeutic goal – improving glycemic control and promoting substantial weight decrease – they exhibit intriguing differences in t